Table II.
Characteristics of patients with suspected COVID-19 symptoms
| Variable | With suspected COVID-19 symptoms | Without suspected COVID-19 symptoms | P∗ | |
|---|---|---|---|---|
| Age, mean ± SD (range), y | 46.6 ± 12.7 (23-77) | 52.8 ± 14.1 (17-84) | .04 | |
| Sex | ||||
| Male, % (n/N) | 62.1 (18/29) | 73.6 (96/130) | .20 | |
| Female, % (n/N) | 37.9 (11/29) | 26.2 (34/130) | .20 | |
| Cardiometabolic comorbidities, % (n/N)† | 13.8 (4/29) | 20.0 (26/130) | .44 | |
| Contact with suspected/confirmed COVID-19 patient, % (n/N) | 62.1 (18/29) | 5.4 (7/130) | <.0001 | |
| Patients who had drug suspended, % (n/N) | 20.7 (6/29) | 2.3 (3/130) | <.0001 | |
| Therapy suspended | Therapy continued | |||
| Age, mean ± SD (range), y | 50.7 ± 14.6 (38-77) | 45.6 ± 12.3 (23-68) | .39 | |
| Sex | ||||
| Male, % (n/N) | 50.0 (3/6) | 65.2 (15/23) | .49 | |
| Female, % (n/N) | 50.0 (3/6) | 34.8 (8/23) | .49 | |
| Suspected COVID-19 symptoms‡ | ||||
| Mild, % (n/N) | 50.0 (3/6) | 95.7 (22/23) | ||
| Moderate, % (n/N) | 33.3 (2/6) | 4.3 (1/23) | .01 | |
| Severe, % (n/N) | 16.7 (1/6) | 0.0 (0/23) | ||
∗
Statistical analysis was performed by t test and χ2 test. Significance value was set at P < .05.
†
Myocardial infarction, stroke, diabetes, obesity, dyslipidemia, or nonalcoholic fatty liver disease.
‡
Suspected COVID-19 symptoms defined as: Mild: flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in ≤7 days without hospitalization. Moderate: flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in 8-16 days without hospitalization. Severe: serious symptoms that required hospitalization; 1 patient reported serious symptoms that required hospitalization (pneumococcal pneumonia with negative COVID-19 nasal swab).